VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway

Neuroendocrinology

Volumn 91, Issue 3, 2010, Pages 268-278

  Villaume, Karine ^a   Blanc, Martine ^a   Gouysse, Géraldine ^a   Walter, Thomas ^a   Couderc, Christophe ^a   Nejjari, Mimoun ^a   Vercherat, Cécile ^a   Cordier Bussat, Martine ^a   Roche, Colette ^a   Scoazec, Jean Yves ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

Angiogenesis; Neuroendocrine cell lines; Octreotide; VEGF mTOR inhibitors

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OCTREOTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; SB 203850; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN; 2-(2-AMINO-3-METHOXYPHENYL)-4H-1-BENZOPYRAN-4-ONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CHROMONE DERIVATIVE; FLAVONOID; IMIDAZOLE DERIVATIVE; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; MORPHOLINE DERIVATIVE; MTOR PROTEIN, MOUSE; PROTEIN SERINE THREONINE KINASE; PYRIDINE DERIVATIVE; SIGNAL PEPTIDE; SOMATOSTATIN; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; GASTROENTEROPANCREATIC ENDOCRINE TUMOR; GROWTH HORMONE SECRETING ADENOMA; HORMONE SYNTHESIS; INTRACELLULAR SPACE; MOUSE; NEUROENDOCRINE TUMOR; NEUROSECRETORY CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; DRUG POTENTIATION; ENZYMOLOGY; PHOSPHORYLATION; RAT; SECRETION (PROCESS); TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; CHROMONES; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMIDAZOLES; INSULIN; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MAP KINASE KINASE 1; MICE; MORPHOLINES; NEUROENDOCRINE TUMORS; OCTREOTIDE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; RATS; SIROLIMUS; SOMATOSTATIN; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953356219     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000289569     Document Type: Article

References (63)

1. Marion-Audibert AM, Barel C, Gouysse G, Dumortier J, Pilleul F, Pourreyron C, Hervieu V, Poncet G, Lombard-Bohas C, Chayvialle JA, Partensky C, Scoazec JY: Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology 2003; 125: 1094-1104.
2. Terris B, Scoazec JY, Rubbia L, Bregeaud L, Pepper MS, Ruszniewski P, Belghiti J, Flejou J, Degott C: Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 1998; 32: 133-138.
3. 2b . J Clin Oncol 2008; 26: 1316-1323.
4. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS: Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26: 3403-3410.
5. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A: Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9: 61-72.
6. Grozinsky-Glasberg S, Shimon I, Korbonits M, Grossman AB: Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer 2008; 15: 701-720.
7. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F: Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008; 26: 4311-4318.
8. Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F: Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 2008; 15: 257-266.
9. Danesi R, Del Tacca M: The effects of the somatostatin analog octreotide on angiogenesis in vitro. Metabolism 1996; 45(suppl 1):49-50.
10. Garcia de la Torre N, Wass JA, Turner HE: Antiangiogenic effects of somatostatin analogues. Clin Endocrinol (Oxf) 2002; 57: 425-441.
11. Woltering EA, Watson JC, Alperin-Lea RC, Sharma C, Keenan E, Kurozawa D, Barrie R: Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. Invest New Drugs 1997; 15: 77-86.
12. Mentlein R, Eichler O, Forstreuter F, Held- Feindt J: Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. Int J Cancer 2001; 19: 545-550. (Pubitemid 32319428)
13. Cascinu S, Del Ferro E, Ligi M, Staccioli MP, Giordani P, Catalano V, Agostinelli R, Muretto P, Catalano G: Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients. Cancer Invest 2001; 268: 8-12.
14. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 81: 128-135.
15. Sabatini DM: mTor and cancer: insights into a complex relationship. Nat Rev Cancer 2006; 6: 729-734.
16. Faivre S, Raymond E: Mechanism of action of rapalogues: the antiangiogenic hypothesis. Expert Opin Investig Drugs 2008; 17: 1619-1621.
17. Poncet G, Villaume K, Walter T, Pourreyron C, Theillaumas A, Lepinasse F, Hervieu V, Cordier-Bussat M, Scoazec JY, Roche C: Angiogenesis and tumor progression in neuroendocrine digestive tumors. J Surg Res 2009; 154: 68-77.
18. Rindi G, Grant SG, Yangaou Y, Ghatei MA, Bloom SR, Bautch VL, Solcia E, Polak JM: Development of neuroendocrine tumors in the gastrointestinal tract of transgenic mice: heterogeneity of hormone expression. Am J Pathol 1990; 136: 1349-1363.
19. Wang H, Iynedjian PB: Modulation of glucose responsiveness of insulinoma β cells by graded overexpression of glucokinase. Proc Natl Acad Sci USA 1997; 94: 4372-4377. (Pubitemid 27194248)
20. Wang H, Maechler P, Ritz-Laser B, Hagenfeldt KA, Ishihara H, Philippe J, Wollheim CB: Pdx1 level defines pancreatic gene expression pattern and cell lineage differentiation. J Biol Chem 2001; 276: 25279-25286.
21. Asfari M, Janjic D, Meda P, Li G, Halban PA, Wollheim CB: Establishment of 2-mercaptoethanol- dependent differentiated insulinsecreting cell lines. Endocrinology 1992; 130: 167-178.
22. Marion-Audibert AM, Nejjari M, Pourreyron C, Anderson W, Gouysse G, Jacquier MF, Dumortier J, Scoazec JY: Effects of endocrine peptides on proliferation, migration and differentiation of human endothelial cells. Gastroenterol Clin Biol 2000; 24: 644-648.
23. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
24. George ML, Eccles SA, Tutton MG, Abulafi AM, Swift RI: Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res 2000; 6: 3147-3152.
25. Christofori G, Naik P, Hanahan D: Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol Endocrinol 1995; 9: 1760-1770.
26. Kuroda M, Oka T, Oka Y, Yamochi T, Ohtsubo K, Mori S, Watanabe T, Machinami R, Ohnishi S: Colocalization of vascular endothelial growth factor (vascular permeability factor) and insulin in pancreatic islet cells. J Clin Endocrinol Metab 1995; 80: 3196-3200.
27. Fan L, Iseki S: Immunohistochemical localization of vascular endothelial growth factor in the endocrine glands of the rat. Arch Histol Cytol 1998; 61: 17-28.
28. Partanen TA, Arola J, Saaristo A, Jussila L, Ora A, Miettinen M, Stacker SA, Achen MG, Alitalo K: VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J 2000; 14: 2087-2096.
29. Katavetin P, Miyata T, Inagi R, Tanaka T, Sassa R, Ingelfinger JR, Fujita T, Nangaku M: High glucose blunts vascular endothelial growth factor response to hypoxia via the oxidative stress-regulated hypoxia-inducible factor/hypoxia-responsible element pathway. J Am Soc Nephrol 2006; 17: 1405-1413.
30. Kurmasheva RT, Harwood FC, Houghton PJ: Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors. Mol Cancer Ther 2007; 50: 1620-1628.
31. Grozinsky-Glasberg S, Franchi G, Teng M, Leontiou CA, Ribeiro de Oliveira A Jr, Dalino P, Salahuddin N, Korbonits M, Grossman AB: Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuroendocrine tumour cell Line. Neuroendocrinology 2008; 87: 168-181.
32. Kumar M, Liu ZR, Thapa L, Chang Q, Wang DY, Qin RY: Antiangiogenic effect of somatostatin receptor subtype 2 on pancreatic cancer cell line: Inhibition of vascular endothelial growth factor and matrix metalloproteinase-2 expression in vitro. World J Gastroenterol 2004; 10: 393-399.
33. Kanashiro CA, Schally AV, Nagy A, Halmos G: Inhibition of experimental U-118MG glioblastoma by targeted cytotoxic analogs of bombesin and somatostatin is associated with a suppression of angiogenic and antiapoptotic mechanisms. Int J Oncol 2005; 27: 169-174.
34. Lawnicka H, Pisarek H, Kunert-Radek J, Pawlikowski M: Effects of somatostatin on vascular endothelial growth factor secretion from non-functioning pituitary tumoral cells incubated in vitro. Neuro Endocrinol Lett 2008; 29: 113-116.
35. Kurosaki M, Saeger W, Abe T, Ludecke DK: Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment. Neurol Res 2008; 20.
36. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ: Octreotide. N Engl J Med 1996; 334: 246-254.
37. La Rosa S, Uccella S, Finzi G, Albarello L, Sessa F, Capella C: Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum Pathol 2003; 34: 18-27.
38. Charland S, Boucher MJ, Houde M, Rivard N: Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen- activated protein kinase activation in normal and tumoral pancreatic acinar cells. Endocrinology 2001; 142: 121-128.
39. Theodoropoulou M, Zhang J, Laupheimer S, Paez-Pereda M, Erneux C, Florio T, Pagotto U, Stalla GK: Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res 2006; 66: 1576-1582.
40. Horiguchi K, Yamada M, Satoh T, Hashimoto K, Hirato J, Tosaka M, Yamada S, Mori M: Transcriptional activation of the mixed lineage leukemia-p27Kip1 pathway by a somatostatin analogue. Clin Cancer Res 2009; 15: 2620-2629.
41. Woods SA, McGlade CJ, Guha A: Phosphatidylinositol 3' -kinase and MAPK/ERK kinase 1/2 differentially regulate expression of vascular endothelial growth factor in human malignant astrocytoma cells. Neuro Oncol 2002; 4: 242-252.
42. Zitzmann K, De Toni EN, Brand S, Goke B, Meinecke J, Spottl G, Meyer HH, Auernhammer CJ: The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 2007; 85: 54-60.
43. Kidd M, Eick GN, Modlin IM, Pfragner R, Champaneria MC, Murren J: Further delineation of the continuous human neoplastic enterochromaffin cell line, KRJ-I, and the inhibitory effects of lanreotide and rapamycin. J Mol Endocrinol 2007; 38: 181-192.
44. Miele C, Rochford JJ, Filippa N, Giorgetti- Peraldi S, Van Obberghen E: Insulin and insulin- like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways. J Biol Chem 2000; 275: 21695-21702.
45. Rak J, Mitsuhashi Y, Sheehan C, Tamir A, Viloria-Petit A, Filmus J, Mansour SJ, Ahn NG, Kerbel RS: Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in rastransformed epithelial cells and fibroblasts. Cancer Res 2000; 60: 490-498.
46. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A: Regulation of glut1 mRNA by hypoxia- inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 2001; 276: 9519-9525.
47. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK: Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 2001; 12: 363-369.
48. Kozawa O, Matsuno H, Uematsu T: Involvement of p70 S6 kinase in bone morphogenetic protein signaling: vascular endothelial growth factor synthesis by bone morphogenetic protein-4 in osteoblasts. J Cell Biochem 2001; 60: 430-436. (Pubitemid 32405760)
49. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E: Insulin stimulates hypoxia-inducible factor-1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 2002; 277: 27975-27981.
50. Burroughs KD, Oh J, Barrett JC, DiAugustine RP: Phosphatidylinositol 3-kinase and MEK1/2 are necessary for insulin-like growth factor-I-induced vascular endothelial growth factor synthesis in prostate epithelial cells: a role for hypoxia-inducible factor- 1? Mol Cancer Res 2003; 1: 312-322.
51. Mottet D, Michel G, Renard P, Ninane N, Raes M, Michiels C: Role of ERK and calcium in the hypoxia-induced activation of HIF-1. J Cell Physiol 2003; 194: 30-44.
52. Li J, Davidson G, Huang Y, Jiang BH, Shi X, Costa M, Huang C: Nickel compounds act through phosphatidylinositol-3-kinase/Aktdependent, p70(S6k)-independent pathway to induce hypoxia inducible factor transactivation and Cap43 expression in mouse epidermal Cl41 cells. Cancer Res 2004; 64: 94-101.
53. Giuliani N, Lunghi P, Morandi F, Colla S, Bonomini S, Hojden M, Rizzoli V, Bonati A: Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Leukemia 2004; 18: 628-635.
54. Hellwig-Burgel T, Stiehl DP, Katschinski DM, Marxsen J, Kreft B, Jelkmann W: VEGF production by primary human renal proximal tubular cells: requirement of HIF-1, PI3- kinase and MAPKK-1 signaling. Cell Physiol Biochem 2005; 15: 99-108.
55. Li J, Tong Q, Shi X, Costa M, Huang C: ERKs activation and calcium signaling are both required for VEGF induction by vanadium in mouse epidermal Cl41 cells. Mol Cell Biochem 2005; 279: 25-33.
56. Ouyang W, Li J, Shi X, Costa M, Huang C: Essential role of PI-3K, ERKs and calcium signal pathways in nickel-induced VEGF expression. Mol Cell Biochem 2005; 279: 35-43.
57. Shi YH, Wang YX, Bingle L, Gong LH, Heng WJ, Li Y, Fang WG: In vitro study of HIF-1 activation and VEGF release by bFGF in the T47D breast cancer cell line under normoxic conditions: involvement of PI-3K/Akt and MEK1/ERK pathways. J Pathol 2005; 205: 530-536.
58. Garcia-Maceira P, Mateo J: Silibinin inhibits hypoxia-inducible factor-1α and mTOR/ p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. Oncogene 2009; 28: 313-324.
59. Jung YD, Nakano K, Liu W, Gallick GE, Ellis LM: Extracellular signal-regulated kinase activation is required for up-regulation of vascular endothelial growth factor by serum starvation in human colon carcinoma cells. Cancer Res 1999; 59: 4804-4807.
60. Mottet D, Dumont V, Deccache Y, Demazy C, Ninane N, Raes M, Michiels C: Regulation of hypoxia-inducible factor-1α protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase-3β pathway in HepG2 cells. J Biol Chem 2003; 278: 31277-31285.
61. Sutton KM, Hayat S, Chau NM, Cook S, Pouyssegur J, Ahmed A, Perusinghe N, Le Floch R, Yang J, Ashcroft M: Selective inhibition of MEK1/2 reveals a differential requirement for ERK1/2 signalling in the regulation of HIF-1 in response to hypoxia and IGF1. Oncogene 2007; 26: 3920-3929.
62. Jung YD, Liu W, Reinmuth N, Ahmad SA, Fan F, Gallick GE, Ellis LM: Vascular endothelial growth factor is upregulated by interleukin-1β in human vascular smooth muscle cells via the P38 mitogen-activated protein kinase pathway. Angiogenesis 2001; 4: 155-162.
63. 1 activated p38 signaling pathway enhances endothelial cell migration. Cancer Res 2001; 61: 1727-1732.